Anavex Life Sciences Corp (AVXL)

[Doc328]

The June 6 PR stayed dosing was complete so a typical 4 week or 30 day final safety visit would have been very early July —-about 21 weeks ago. 6-12 weeks after last patient visit is typical for top line data release.

Missling has blamed the CRO for Avatar and the. 2b AD trial issues and delays so no surprise if he blames them for Excellence.

NEW YORK – June 6, 2023
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced the completion of dosing of all participants of the placebo-controlled EXCELLENCE Phase 2/3 study ANAVEX®2-73-RS-003 in pediatric patients with Rett syndrome.